Atypical antipsychotics in the treatment of early-onset schizophrenia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10295007" target="_blank" >RIV/00216208:11130/15:10295007 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/15:10295007
Result on the web
<a href="http://dx.doi.org/10.2147/NDT.S82185" target="_blank" >http://dx.doi.org/10.2147/NDT.S82185</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/NDT.S82185" target="_blank" >10.2147/NDT.S82185</a>

Result language
angličtina
Original language name
Atypical antipsychotics in the treatment of early-onset schizophrenia
Original language description
Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the randomized, double-blind, controlled studies of AAPs in EOS, including clozapine, risperidone, olanzapine, aripiprazole, paliperidone, quetiapine, and ziprasidone. No significant differences in efficacy between AAPs were found, with the exception of clozapine and ziprasidone. Clozapine demonstrated superior efficacy in treatment-resistant patients with EOS, whereas ziprasidone failedto demonstrate efficacy in the treatment of EOS. Our review also focuses on the onset of action and weight gain associated with AAPs. The data on onset of action of AAPs in pediatric psychiatry are scanty and inconsistent. Olanzapine appears to cause the most significant weight gain in patients with EOS, while ziprasidone and aripiprazole seem to cause the least.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FL - Psychiatry, sexology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)